Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 701–800 of 1,001
Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening
Zawawi, S. S. A., Salleh, E. A., & Musa, M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00226 · Cited by 27
Lee, S., Kim, K., Lee, E., Lee, K., Ahn, K. H., Park, H., Kim, Y., Shin, S., Jeon, S. Y., Hwang, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00609-7 · Cited by 36
“As a result, PDOs hold promise as a functional precision medicine technology for guiding treatment decisions 2,7 .”
Applications of Organoids in Advancing Drug Discovery and Development
Gopallawa, I., Gupta, C., Jawa, R., Cyril, A., Jawa, V., Chirmule, N. B., & Gujar, V. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.06.016 · Cited by 30
Technological advances and challenges in constructing complex gut organoid systems
Zheng, L., Zhan, Y., Wang, C., Fan, Q., Sun, D., Li, Y., & Xiong, Y. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1432744 · Cited by 29
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 32
“CRC studies report a timeframe from around 2 weeks up to 53 weeks [19, 21, 164, 165] with a median time of 9 weeks [164] for the entire process.”
BackgroundMethodInfluentialYao, N., Jing, N., Lin, J., Niu, W., Yan, W., Yuan, H., Xiong, Z., Hou, Q., Qiao, X., Liu, Q., et al. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01523-w · Cited by 33
“The PDTOs cultured by submerged Matrigel not only can recapitulate the histological, genetic, and phenotypic characteristics of original tumors, but also can model the patient response to clinical treatment, thus promoting disease modeling and drug screening [9, 11, 17, 27].”
Artificial Intelligence in Organoid-Based Disease Modeling: A New Frontier in Precision Medicine
Balkhair, O., & Albalushi, H. (2025) · Biomimetics · doi:10.3390/biomimetics10120845 · Cited by 36
“They use reproducible differentiation methods and controlled microenvironments and have demonstrated predictive value in disease and drug response studies [105,106].”
Microfluidic device for expedited tumor growth towards drug evaluation
Uhl, C. G., & Liu, Y. (2019) · Lab on a Chip · doi:10.1039/c8lc01250d · Cited by 27
Calpe, B., & Kovacs, W. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1756769 · Cited by 30
“pitulate the original tumor architecture, heterogeneity, and drug response [97], the difficulty in creating large amounts of homo-”
BackgroundSimpson, L. W., Szeto, G. L., Boukari, H., Good, T. A., & Leach, J. B. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.05.030 · Cited by 25
Marshall, L. J., Triunfol, M., & Seidle, T. (2020) · Animals · doi:10.3390/ani10101923 · Cited by 29
Nikulin, S. V., Alekseev, B. Y., Sergeeva, N. S., Karalkin, P. A., Nezhurina, E. K., Kirsanova, V. A., Sviridova, I. K., Akhmedova, S. A., Волченко, Н. Н., Болотина, Л. В., et al. (2020) · Biochimie · doi:10.1016/j.biochi.2020.10.007 · Cited by 25
The Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis
Ojo, B. A., VanDussen, K. L., & Rosen, M. J. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab161 · Cited by 45
Development of patient‑derived tumor organoids and a drug testing model for renal cell carcinoma
Kazama, A., Anraku, T., Kuroki, H., Shirono, Y., Murata, M., Bilim, V. N., Ugolkov, A. V., Saito, K., & Tomita, Y. (2021) · Oncology Reports · doi:10.3892/or.2021.8177 · Cited by 27
Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept
Puch, C. B. M. D., Vanderstraete, M., Giraud, S., Lautrette, C., Christou, N., & Mathonnet, M. (2021) · Theranostics · doi:10.7150/thno.55954 · Cited by 29
“ambitious study demonstrated the representativity of patient-derived organoid models of CRC and gastroesophageal cancers [141].”
BackgroundApplication Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 34
“(Vlachogiannis et al., 2018) used 110 fresh biopsy samples from 71 metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in four prospective phases I/II clinical trials to establish a living organoid biobank of CRC.”
BackgroundMethodResultInfluentialOkamoto, T., Natsume, Y., Doi, M., Nosato, H., Iwaki, T., Yamanaka, H., Yamamoto, M., Kawachi, H., Noda, T., Nagayama, S., et al. (2022) · Cancer Science · doi:10.1111/cas.15396 · Cited by 28
Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer
Seidlitz, T., Schmäche, T., García, F., Lee, J. H., Qin, N., Kochall, S., Fohgrub, J., Pauck, D., Rothe, A., Koo, B., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215705 · Cited by 27
Multi-compartment tumor organoids
Lee, M., Russo, G. C., Rahmanto, Y. S., Du, W., Crawford, A. J., Wu, P., Gilkes, D. M., Kiemen, A. L., Miyamoto, T., Yu, Y., et al. (2020) · Materials Today · doi:10.1016/j.mattod.2022.07.006 · Cited by 23
Cancer organoid applications to investigate chemotherapy resistance
Harada, K., & Sakamoto, N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1067207 · Cited by 26
“Generation of xenografts from organoids has enabled testing of the antitumor effects of regorafenib, an anti-angiogenic drug, and the prognosis of treated mice has been reported to correlate with clinical outcomes (Vlachogiannis et al., 2018).”
BackgroundTaverna, J. A., Hung, C., Williams, M. H., Williams, R., Chen, M., Kamali, S., Sambandam, V., Chiu, C. H.-L., Osmulski, P. A., Gaczynska, M. E., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2024.107533 · Cited by 36
Organoid in colorectal cancer: progress and challenges
Ji, D., & Wu, A. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000882 · Cited by 28
Gil, D. A., Deming, D. A., & Skala, M. C. (2021) · Journal of Biomedical Optics · doi:10.1117/1.jbo.26.3.036005 · Cited by 25
“Functional drug screens using PCOs, which reflect the heterogeneity and drug sensitivity of in vivo tumors, could be used to predict the most effective treatment for a patient and identify novel drug candidates during drug development.(5,6,8,10,12) However, current methods for evaluating drug response in PCOs are dest…”
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24
Patient-derived tumor models and their distinctive applications in personalized drug therapy
He, J., Zhang, C., Özkan, A., Feng, T., Duan, P., Wang, S., Yang, X., Xie, J., & Liu, X. (2023) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2023.100014 · Cited by 28
Organoid-Based Assessment of Metal–Organic Framework (MOF) Nanomedicines for Ex Vivo Cancer Therapy
Li, D., Zhang, R., Le, Y., Zhang, T., Luo, D., Zhang, H., Li, J., Zhao, R., Hu, Y., & Kong, X. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c05172 · Cited by 27
Paola, F. J. D., Calafato, G., Piccaluga, P. P., Tallini, G., & Rhoden, K. J. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080394 · Cited by 27
“…predict patient response in the clinic has been shown in several studies, using metastatic chemo-refractory gastrointestinal tumor-PDO biobanks [27], locally advanced rectal cancer-PDO biobanks from patients treated with neoadjuvant chemoradiation [20], advanced CRC-PDO biobanks [21,24] and…”
Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions
Detjen, K. M., Hammerich, L., Özdirik, B., Demir, M., Wiedenmann, B., Tacke, F., Jann, H., & Roderburg, C. (2020) · Neuroendocrinology · doi:10.1159/000509864 · Cited by 23
Systems Biology and Experimental Model Systems of Cancer
Yalçın, G. D., Danisik, N., Baygin, R. C., & Acar, A. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040180 · Cited by 27
“In addition, studies focused on comparing the histopathological features of tumors with PDOs revealed that the PDOs maintain similar morphological characteristics as the original tumor [90,91].”
BackgroundZeng, L., Liao, Q., Zhao, H., Jiang, S., Yang, X., Tang, H., He, Q., Yang, X., Fang, S., He, J., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0566 · Cited by 24
Truelsen, S. L. B., Mousavi, N., Wei, H., Harvey, L., Stausholm, R., Spillum, E., Hagel, G., Qvortrup, K., Thastrup, M., Harling, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253258 · Cited by 26
Hemelryk, A. V., Mout, L., Erkens‐Schulze, S., French, P. J., van Weerden, W. M., & van Royen, M. E. (2021) · Biomolecules · doi:10.3390/biom11111572 · Cited by 28
Specific metabolic response of patient-derived organoids to curcumin of colorectal cancer
Chen, L., Dai, Z., Ge, C., Huang, D., Zhou, X., Pan, K., Xu, W., Fu, J., & Du, J. L. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123260 · Cited by 27
Moy, R. H., Nguyen, A., Loo, J. M., Yamaguchi, N., Kajba, C. M., Santhanam, B., Ostendorf, B. N., Wu, Y. G., Tavazoie, S., & Tavazoie, S. F. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.04.010 · Cited by 24
Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research
Forsythe, S. D., Erali, R. A., Laney, P., Sivakumar, H., Li, W., Skardal, A., Söker, S., & Votanopoulos, K. I. (2022) · Scientific Reports · doi:10.1038/s41598-022-17921-6 · Cited by 27
Xu, X., Wang, S., Zhou, J., Chen, J., Huang, Y., Kumari, R., Mao, B., Zheng, M., wang, J., tu, X., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279821 · Cited by 29
“PDXs and PDOs independently have been reported to share similar histo-/molecular pathology to the original patient tumors [3, 5, 19, 23, 24, 28, 44].”
BackgroundEngineered materials to model human intestinal development and cancer using organoids
Cruz‐Acuña, R., & García, A. J. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.02.017 · Cited by 23
do Amaral, R. L. F., Zimmermann, M., Ma, A., Zhang, H., Swiech, K., & Pan, C.-X. (2020) · Cancers · doi:10.3390/cancers12051304 · Cited by 25
“Likewise, rece t studies have reported a positive correlation in co-clinical trials between a patient’s response to treatment and r sults obt in d in preclinical trials using patient-d rived cells cultured in 3D models [53,54].”
BackgroundRational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
Abbasian, M. H., Sobhani, N., Sisakht, M. M., D’Angelo, A., Sirico, M., & Roudi, R. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10805-4 · Cited by 29
“This similarity translated to accurate predictions of patient response to targeted agents or chemotherapy, with 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predic - tive value [53].”
Zhao, K.-Y., Du, Y., Cao, H., Su, L., Su, X., & Li, X. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114435 · Cited by 31
Cellpose as a reliable method for single-cell segmentation of autofluorescence microscopy images
Riendeau, J. M., Gillette, A. A., Guzman, E. C., Cruz, M. C., Kralovec, A., Udgata, S., Schmitz, A., Deming, D. A., Cimini, B. A., & Skala, M. C. (2025) · Scientific Reports · doi:10.1038/s41598-024-82639-6 · Cited by 34
Qi, Y., Yan, J., Huang, X., Jiang, X., Li, R., Wan, J., Li, Y., Miao, Z., Song, Z., Liu, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107788 · Cited by 23
Banda, M., McKim, K. L., Myers, M. B., Inoue, M., & Parsons, B. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238862 · Cited by 24
Lampis, A., Hahne, J. C., Gasparini, P., Cascione, L., Hedayat, S., Vlachogiannis, G., Murgia, C., Fontana, E., Edwards, J., Horgan, P. G., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00820-0 · Cited by 24
Self-citationModeling colorectal cancer: A bio‐resource of 50 patient‐derived organoid lines
Engel, R. M., Jardé, T., Oliva, K., Kerr, G., Chan, W. H., Hlavca, S., Nickless, D. K., Archer, S. K., Yap, R. J., Ranchod, P., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15818 · Cited by 23
“7,27,30,31 Interestingly, PDCOs derived from dMMR patients continue to acquire variants at a high rate in culture; therefore, it remains to be determined how long these PDCOs continue to be representative of the primary tumor.”
BackgroundLiu, H.-Y., Wang, F.-H., Liang, J.-M., Xiang, Y., Liu, S., Zhang, S., Zhu, C., He, Y., & Zhang, C. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04124-9 · Cited by 26
Ludikhuize, M. C., Gevers, S., Nguyen, N. B., Meerlo, M., Roudbari, S. K. S., Gülersönmez, M. C., Stigter, E. C. A., Drost, J., Clevers, H. C., Burgering, B. M. T., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04055-8 · Cited by 24
Making In Vitro Tumor Models Whole Again
Wu, K. Z., Adine, C., Mitriashkin, A., Aw, B. J. J., Iyer, N. G., & Fong, E. L. S. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202279 · Cited by 25
Lim, H. J., Zhuang, L., & Fitzgerald, R. C. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02622-3 · Cited by 33
“Furthermore, organoids maintain the sensitivity of the original tumour to drugs making it an ideal tool for functional drug screening to identify therapeutic targets for implementation in clinical practice [76].”
BackgroundUse and application of organ-on-a-chip platforms in cancer research
Yu, Y., Zhou, T., & Cao, L.-L. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00790-7 · Cited by 31
“…drugs with the responses of patients in clinical trials, researchers demonstrated that PDOs treated with anticancer regimens recapitulated patient responses in clinical trials (Bruun et al. 2020; Chen et al. 2021; Kim et al. 2021; Li et al. 2022, 2023; Vlachogiannis et al. 2018; Yao et al. 2020).”
BackgroundRao, X., Qiao, Z., Yang, Y., Deng, Y., Zhang, Z., Yu, X., & Guo, X. (2024) · Pharmaceuticals · doi:10.3390/ph17020225 · Cited by 30
“…team demonstrated the effectiveness of PDOs in guiding clinical treatment for patients with metastatic gastrointestinal cancer, high-lighting the high accuracy of organoid drug screening with 93% specificity, 100% sensitivity, 88% positive predictive value, and 100% negative predictive value [43].”
BackgroundVarinelli, L., Battistessa, D., Guagliò, M., Zanutto, S., Illescas, O., Lorenc, E., Pisati, F., Kusamura, S., Cattaneo, L., Sabella, G., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03052-5 · Cited by 24
Li, Y., Wang, R., Huang, D., Ma, X., Mo, S., Guo, Q., Fu, G., Li, Y., Xu, X., Hu, X., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz178 · Cited by 23
Cholangiocarcinoma Disease Modelling Through Patients Derived Organoids
Amato, F., Rae, C. J., Prete, M. G., & Braconi, C. (2020) · Cells · doi:10.3390/cells9040832 · Cited by 22
“Improvements of protocols for 3D organotypic cultures allowed researchers to obtain cancer organoids directly from patient biopsy material providing individualized cancer models that reproduce interpatient heterogeneity [25,26].”
BackgroundSelf-citationPan, B., Zhao, D., Liu, Y., Li, N., Song, C., Li, N., Li, X., & Zhao, Z. (2021) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-021-00563-9 · Cited by 31
Nojima, Y., Yao, R., & Suzuki, T. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167693 · Cited by 28
A New Perspective on Precision Medicine: The Power of Digital Organoids
Yang, Q., Li, M., Xiao, Z., Feng, Y., Lei, L., & Li, S. (2025) · Biomaterials Research · doi:10.34133/bmr.0171 · Cited by 26
“ASC-derived organoids closely resemble the normal physiological state of the human body and are commonly used in infectious diseases [ 42 , 43 ], genetic diseases [ 44 , 45 ], disease modeling [ 46 – 48 ], regenerative medicine [ 49 ], and human body development [ 50 , 51 ].”
Human Organoids and Their Application in Tumor Models, Disease Modeling, and Tissue Engineering
Song, S., Liu, Z., Wang, Y., & Gong, B. (2025) · Medicine Bulletin · doi:10.1002/mdb2.70001 · Cited by 32
Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids
Hill, S. J., & D’Andrea, A. D. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0527 · Cited by 23
“Previous studies have demonstrated that organoids can partially predict the clinical response of metastatic gastrointestinal cancers to chemotherapy or to targeted therapy (11).”
BackgroundThe Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development
Zhou, Z., Zhu, J., Jiang, M., Sang, L., Hao, K., & He, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050704 · Cited by 23
“Organoids derived from colorectal and gastroesophageal cancer patients have been used as preclinical models to predict the clinical responses [53].”
MethodMultiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma
Armstrong, A., Haque, M. R., Mirbagheri, S., Barlass, U., Gilbert, D. Z., Amin, J. P., Singh, A., Naqib, A. D., & Bishehsari, F. (2021) · Biomedicines · doi:10.3390/biomedicines9070705 · Cited by 22
“We and others have shown that organoids retain a high degree of similarity to the original tissue and the patient tumors, including PDA [7,8].”
Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine
Kiwaki, T., & Kataoka, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050695 · Cited by 26
Hao, M., Cao, Z., Wang, Z. P., Xin, J., Kong, B., Xu, J., Zhang, L., & Chen, P. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00354 · Cited by 26
Modeling microbiota-associated human diseases: from minimal models to complex systems
Aguanno, D., Metwaly, A., Coleman, O. I., & Haller, D. (2022) · Microbiome Research Reports · doi:10.20517/mrr.2022.01 · Cited by 25
Tumor Organoid Model and Its Pharmacological Applications in Tumorigenesis Prevention
Cao, X., Zheng, W., Qiang, Y., Yao, N., Zuo, F., & Qiu, S. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220803125822 · Cited by 25
Paty, P. B., & García‐Aguilar, J. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27079 · Cited by 25
Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Peng, K., Zhang, F., Wang, Y., Sahgal, P., Li, T., Zhou, J. R., Liang, X., Zhang, Y., Sethi, N. S., Liu, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1609 · Cited by 24
Will Organoids Fill the Gap towards Functional Precision Medicine?
Papaccio, F., Cabeza-Segura, M., García-Micó, B., Tarazona, N., Roda, D., Castillo, J., & Cervantes, A. M. R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111939 · Cited by 25
Organoids technology for advancing the clinical translation of cancer nanomedicine
Zhao, D., Liang, J., Huang, X., Shen, S., & Wang, J. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1892 · Cited by 27
In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced
Arutyunyan, I. V., Jumaniyazova, E. D., Макаров, А. В., & Fatkhudinov, T. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111575 · Cited by 23
“In a pilot study, organoids obtained from 21 patients with gastrointestinal tumors predicted response to various types of chemotherapy with 100% sensitivity and 93% specificity [125].”
BackgroundZieger, V., Frejek, D., Zimmermann, S., Miotto, G., Koltay, P., Zengerle, R., & Kartmann, S. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303350 · Cited by 21
Bioprinted research models of urological malignancy
Wang, G., Mao, X., Wang, W., Xiaolong, W., Li, S., & Wang, Z. (2024) · Exploration · doi:10.1002/exp.20230126 · Cited by 31
Ding, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.052 · Cited by 24
de Kort, W. W. B., Spelier, S., Devriese, L. A., van Es, R. J. J., & Willems, S. M. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00518-6 · Cited by 23
“This enables correlating in vitro organoid drug response to the response of patients in the clinic, as shown in a clinical study for organoids derived from gastrointestinal cancer [124].”
BackgroundInnovating cancer drug discovery with refined phenotypic screens
Wang, Z., Hulíková, A., & Swietach, P. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.06.001 · Cited by 25
Microdissection tools to generate organoids for modeling the tumor immune microenvironment
Cordts, S. C., Yuki, K., Echeverri, M. F. H., Narasimhan, B., Kuo, C. J., & Tang, S. K. Y. (2024) · Microsystems & Nanoengineering · doi:10.1038/s41378-024-00756-8 · Cited by 22
“Prior studies have assembled organoids (or spheroids) from single tumor cells that lack stroma and cocultured them with peripheral immune populations 19 – 21 .”
Genetically modified organoids for tissue engineering and regenerative medicine
Zhang, Q., Jin, H., Zhu, D., Chen, Y., Fu, M., Lu, S., Qiu, Y., Zhou, G., Yang, G., & Jiang, Z. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103337 · Cited by 26
Choi, Y., Na, D., Yoon, G., Kim, J., Min, S., Yi, H., Cho, S., Cho, J. H., Lee, C., & Jang, J. (2025) · Advanced Science · doi:10.1002/advs.202411769 · Cited by 36
LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models
Shin, A. E., Sugiura, K., Kariuki, S. W., Cohen, D. A., Flashner, S. P., Klein–Szanto, A. J., Nishiwaki, N., De, D., Vasan, N., Gabre, J. T., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186035 · Cited by 25
“Their study found that PDOs had a high degree of similarity to patients’ tumors and accurately predicted clinical responses to targeted agents or chemotherapy with a sensitivity of 100%, specificity of 93%, positive predictive value of 88%, and negative predictive value of 100% (62).”
Organoids technology in cancer research: from basic applications to advanced ex vivo models
Varinelli, L., Illescas, O., Lorenc, E., Battistessa, D., Bella, M. D., Zanutto, S., & Gariboldi, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1569337 · Cited by 24
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Lin, J.-X., Yoon, C., Li, P., Ryeom, S. W., Cho, S., Zheng, C., Xie, J., Wang, J.-B., Lu, J., Chen, Q., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0963-y · Cited by 22
RetractedA Tissue Engineering Approach to Metastatic Colon Cancer
Sarvestani, S. K., DeHaan, R. K., Miller, P. G., Bose, S., Shen, X., Shuler, M. L., & Huang, E. H. (2020) · iScience · doi:10.1016/j.isci.2020.101719 · Cited by 22
Novel organoid model in drug screening: Past, present, and future
Nie, X., Liang, Z., Li, K., Yu, H., Huang, Y., Ye, L., & Yang, Y. (2021) · Liver Research · doi:10.1016/j.livres.2021.05.003 · Cited by 23
3D Tumor Models for Breast Cancer: Whither We Are and What We Need
Balachander, G. M., Kotcherlakota, R., Nayak, B., Kedaria, D., Rangarajan, A., & Chatterjee, K. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00230 · Cited by 23
Alkan, A., Hofving, T., Angenete, E., & Yrlid, U. (2021) · Biomarker Research · doi:10.1186/s40364-021-00313-9 · Cited by 25
“Drug-screening results from patient-derived organoids derived from gastrointestinal cancers also matched that of corresponding patient tumours [173].”
ResultChemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Mayr, C., Kiesslich, T., Modest, D. P., Stintzing, S., Ocker, M., & Neureiter, D. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2034785 · Cited by 22
“A possible approach in the future represents patient-derived xenografts or patient-derived organoids (PDO) to reliably test and to monitor all of these aspects in a laboratory setting [117,118].”
BackgroundOrganoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?
Tran, B. M., Deliyannis, G., Hachani, A., Earnest, L., Torresi, J., & Vincan, E. (2022) · Organoids · doi:10.3390/organoids1010002 · Cited by 22
The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression
Mancarella, S., Serino, G., Coletta, S., Armentano, R., Dituri, F., Ardito, F., Ruzzenente, A., Fabregat, I., & Giannelli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084187 · Cited by 24
“Establishment, Culture, and Treatment of Human iCCA-PDOs The establishment and culture of PDOs from iCCA cancers were performed as previously described [38].”
MethodGATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
Bianco, G., Coto‐Llerena, M., Gallon, J., Kancherla, V., Taha‐Mehlitz, S., Marinucci, M., Konantz, M., Srivatsa, S., Montazeri, H., Panebianco, F., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03296-x · Cited by 29
“It is well known that in normal conditions p53 and the PI3K/Akt/mTOR pathway co-regulate cell cycle arrest and apoptosis leading to homeostasis between cell death and survival (Feng et al., 2005; Vousden and Lu, 2002).”
BackgroundFunctional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Flobak, Å., Skånland, S. S., Hovig, E. J., Taskén, K., & Russnes, H. G. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.08.009 · Cited by 31
Flores-Torres, S., Jiang, T., Kort-Mascort, J., Yang, Y. K., Peza-Chavez, O., Pal, S., Mainolfi, A., Pardo, L. A., Ferri, L. E., Bertos, N., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00998 · Cited by 25
Organoids: Construction and Application in Gastric Cancer
Huo, C., Zhang, X., Gu, Y., Wang, D., Zhang, S., Liu, T., Li, Y., & He, W. (2023) · Biomolecules · doi:10.3390/biom13050875 · Cited by 27
“[16] Biopsy ASC TrypLE Whole genome sequencing Drug testing Targeted therapy testing Biobank establishment”
BackgroundZhang, S., Xu, G., Wu, J., Liu, X., Fan, Y. Z., Chen, J., Wallace, G. G., & Gu, Q. (2023) · Small Methods · doi:10.1002/smtd.202300685 · Cited by 28
Organoids as a tool to study homeostatic and pathological immune–epithelial interactions in the gut
Kromann, E. H., Peña‐Cearra, A., & Neves, J. F. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad118 · Cited by 29
“Furthermore, patient-derived organoids have also emerged as a powerful model to study genetics, cellular, and molecular mechanisms behind CRC as they are easy to manipulate and closely mimic human CRC tumors [93].”
BackgroundAdvancements in 3D In Vitro Models for Colorectal Cancer
Vitale, S., Calapà, F., Colonna, F., Luongo, F., Biffoni, M., Maria, R. D., & Fiori, M. E. (2024) · Advanced Science · doi:10.1002/advs.202405084 · Cited by 23
Eckhardt, B. L., Gagliardi, M. E., Iles, L. R., Evans, K. W., Ivan, C., Liu, X., Liu, C., Souza, G. R., Rao, A. U. K., Meric‐Bernstam, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195932 · Cited by 23
Biophysical nanotools for single-molecule dynamics
Su, Q. P., & Ju, L. A. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0447-y · Cited by 22
Preclinical pharmacology modeling of chimeric antigen receptor T therapies
Kumari, R., Ouyang, X., Wang, J., Xu, X., Zheng, M., An, X., & Li, Q. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.08.008 · Cited by 21
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.